Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.
von Itzstein MS, Burns TF, Dowell JE, Horn L, Camidge DR, York SJ, Eaton KD, Kyle K, Fattah FJ, Liu J, Mu-Mosley H, Gupta A, Nadeem U, Gao A, Zhang S, Gerber DE. von Itzstein MS, et al. Among authors: horn l. Clin Cancer Res. 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722. Online ahead of print. Clin Cancer Res. 2024. PMID: 39651955
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC.
Stinchcombe TE, Doebele RC, Wang X, Gerber DE, Horn L, Camidge DR. Stinchcombe TE, et al. Among authors: horn l. J Thorac Oncol. 2021 Jan;16(1):156-161. doi: 10.1016/j.jtho.2020.09.018. Epub 2020 Oct 8. J Thorac Oncol. 2021. PMID: 33039599 Free article. Clinical Trial.
First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. Iams WT, et al. Among authors: horn l. Clin Lung Cancer. 2018 Nov;19(6):531-543. doi: 10.1016/j.cllc.2018.08.011. Epub 2018 Aug 22. Clin Lung Cancer. 2018. PMID: 30197261 Free PMC article.
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Morgensztern D, et al. Among authors: horn l. J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405. J Thorac Oncol. 2015. PMID: 25535693 Free PMC article.
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH. Patel JD, et al. Among authors: horn l. Clin Lung Cancer. 2020 Nov;21(6):520-526. doi: 10.1016/j.cllc.2020.06.007. Epub 2020 Jun 12. Clin Lung Cancer. 2020. PMID: 32807654 Free PMC article. Clinical Trial.
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Heist RS, et al. Among authors: horn l. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26. J Clin Oncol. 2017. PMID: 28548889 Clinical Trial.
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Janjigian YY, et al. Among authors: horn l. Cancer Discov. 2014 Sep;4(9):1036-45. doi: 10.1158/2159-8290.CD-14-0326. Epub 2014 Jul 29. Cancer Discov. 2014. PMID: 25074459 Free PMC article. Clinical Trial.
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H. Karlovich C, et al. Among authors: horn l. Clin Cancer Res. 2016 May 15;22(10):2386-95. doi: 10.1158/1078-0432.CCR-15-1260. Epub 2016 Jan 8. Clin Cancer Res. 2016. PMID: 26747242 Free PMC article. Clinical Trial.
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR. Gerber DE, et al. Among authors: horn l. Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177. Ann Oncol. 2018. PMID: 29767677 Free PMC article. Clinical Trial.
1,354 results